Antibody-drug Conjugates (ADC)

NO2-SPDB-sulfo is a cleavable antibody-drug conjugate (ADC) linker designed for efficient conjugation of cytotoxic drugs to antibodies. This linker facilitates the selective release of the drug in the target environment, promoting enhanced therapeutic efficacy while minimizing off-target effects. It is widely utilized in research and development of ADCs for targeted cancer therapy.

MP-Ala-Ala-PAB is a cleavable linker specifically designed for use in antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing off-target effects. Its ability to be cleaved under specific conditions makes it a valuable component in the development of effective ADC formulations in cancer research.

N-Cbz-glycyl-glycyl-D-phenylalanine functions as a cleavable linker for antibody-drug conjugates (ADCs). This compound facilitates the targeted delivery of cytotoxic agents to cancer cells, enhancing therapeutic efficacy while minimizing systemic toxicity. Its design allows for selective cleavage in the presence of tumor-specific conditions, making it a valuable tool in cancer research and ADC development.

MC-PEG2-C2-NHS ester is a non-cleavable 2-unit polyethylene glycol (PEG) linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This linker facilitates the site-specific attachment of therapeutic agents to antibodies, enhancing the stability and pharmacokinetics of the resulting conjugates. Its application is critical in developing targeted therapies for cancer and other diseases, allowing for improved delivery and efficacy of biologic drugs.

STI-8811 is a highly efficient drug-linker designed for the synthesis of antibody-drug conjugates (ADCs). It facilitates the covalent attachment of therapeutic agents to antibodies, enhancing the specificity and efficacy of targeted cancer treatments. This linker is essential for researchers focused on developing innovative ADC formulations that can improve therapeutic outcomes in oncology.

Propargyl-PEG24-acid is a versatile ADC linker that features a polyethylene glycol (PEG) chain. This compound facilitates the synthesis of antibody-drug conjugates (ADCs) by providing a stable yet flexible connection between the antibody and cytotoxic agents. Its applications in drug development include enhancing therapeutic efficacy while minimizing off-target effects, making it a valuable tool for researchers in the field of targeted cancer therapies.

Aminooxy-PEG2-alcohol serves as a non-cleavable linker designed for antibody-drug conjugates (ADCs). This 2 unit polyethylene glycol (PEG) linker facilitates the efficient conjugation of antibodies to cytotoxic drugs, enhancing targeted delivery in therapeutic applications. Additionally, Aminooxy-PEG2-alcohol functions as a PEG-based linker for the synthesis of PROTACs, providing a versatile tool for research in targeted protein degradation and drug development.

Ald-Ph-amido-PEG4-propargyl is a non-cleavable polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) synthesis. This reagent features an alkyne group that enables its use in click chemistry, specifically the copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application facilitates the stable attachment of therapeutic agents to antibodies, enhancing the efficacy of targeted cancer therapies.

PC Biotin-PEG3-alkyne is a cleavable antibody-drug conjugate (ADC) linker featuring a three-unit polyethylene glycol (PEG) chain. This linker incorporates an alkyne group that enables click chemistry reactions, specifically copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing compounds. It is designed for the synthesis of ADCs, facilitating targeted drug delivery in various biological research applications.

Boc-gly-PEG3-endo-BCN is a cleavable PEG-based linker designed for targeted protein degradation applications through PROTAC technology. Its biocompatible structure facilitates the synthesis of antibody-drug conjugates (ADCs) by serving as a versatile linker. The presence of a bicyclo[6.1.0]nonyne (BCN) group allows for efficient strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with azide-containing molecules, making it a valuable reagent for click chemistry in biological research.

Mal-CO-PEG5-NHS ester is a non-cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). It comprises a 5-unit polyethylene glycol (PEG) chain that facilitates the conjugation of therapeutic agents to antibodies. This reagent is essential for enhancing the solubility and stability of ADCs, thereby improving their pharmacokinetic profiles and therapeutic efficacy in targeted cancer therapies.

Ald-Ph-amido-PEG2 is a non-cleavable linker designed for antibody-drug conjugates (ADCs). This linker facilitates stable conjugation between antibodies and therapeutic agents, ensuring prolonged circulation and targeted delivery to cancer cells. It is especially useful in the development of ADCs aimed at overcoming challenges related to drug release and bioavailability in therapeutic applications.

THP-SS-PEG1-Boc is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This 1 unit PEG linker features a thiol-sensitive disulfide bond, enabling controlled drug release upon cellular internalization. It is ideal for applications in targeted therapy, improving the delivery and efficacy of therapeutic agents in cancer treatment research.

Acid-PEG3-SS-PEG3-acid is a cleavable linker designed for use in antibody-drug conjugates (ADCs). Comprising six units of polyethylene glycol (PEG) and featuring a disulfide bond, it enables the release of the cytotoxic payload within the target cells. This linker is valuable for enhancing the solubility and stability of ADCs, optimizing their therapeutic efficacy in cancer research and treatment development.

Gly-PEG3-amine is a cleavable linker consisting of a three-unit polyethylene glycol (PEG) chain, specifically designed for use in the synthesis of antibody-drug conjugates (ADCs). This reagent allows for effective drug attachment while facilitating controlled release of the cytotoxic agent in target cells. Gly-PEG3-amine is essential for improving the therapeutic index of ADCs, ensuring precise delivery and enhanced efficacy in various cancer research applications.

N-Boc-Val-Dil-Dap-Doe is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic drugs to monoclonal antibodies, ensuring effective delivery targeting tumor cells. Its biosynthetic applications are crucial in the development of targeted cancer therapies, enhancing therapeutic efficacy while minimizing systemic toxicity.

Mal-PEG2-azide is a polyethylene glycol (PEG) based azide linker specifically designed for antibody-drug conjugate (ADC) synthesis. This compound facilitates efficient conjugation through the click chemistry approach, enabling the formation of stable and targeted ADCs. Mal-PEG2-azide is particularly useful in research applications focused on improving the therapeutic efficacy and selectivity of anticancer agents.

Fmoc-aminooxy-PEG2-NH2 is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an aminooxy functional group that facilitates selective conjugation to antibody moieties. Its polyethylene glycol (PEG) spacer enhances solubility and stability, making it suitable for various therapeutic applications. This reagent is ideal for researchers focused on developing targeted drug delivery systems in cancer therapy.

DBCO-PEG3-C1-acid is an efficient ADC linker designed to facilitate strain-promoted azide-alkyne click reactions. This reagent serves as a powerful tool in the development of antibody-drug conjugates, enhancing target specificity and therapeutic efficacy. Its biocompatible PEG spacer provides solubility and flexibility, making it ideal for conjugating various cytotoxic agents for targeted cancer therapy applications.

SPDMV-sulfo is a glutathione-cleavable linker designed for antibody-drug conjugates (ADCs). This compound facilitates the release of drug payloads in chemically controlled environments, significantly enhancing therapeutic efficacy. It is particularly valuable in cancer research, where selective targeting and controlled drug delivery are critical for minimizing off-target effects. SPDMV-sulfo enables the development of innovative ADC formulations for improving treatment strategies.

Basivarsen linker is an innovative linker designed for antibody-drug conjugates (ADCs). It facilitates the coupling of a transferrin receptor 1 (TfR1) binding Fab and an antisense oligonucleotide, forming the basis of the antibody-oligonucleotide conjugate (AOC) Zeleciment basivarsen. This conjugate specifically targets mutant nuclear myotonic dystrophy protein kinase (DMPK) RNA, promoting its degradation through RHase H and aiming to correct splicing abnormalities. Basivarsen linker is essential for research into myotonic dystrophy type 1 (DM1) and its therapeutic approaches.

Propargyl-PEG1-SS-alcohol is a cleavable 1 unit PEG linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an alkyne group that enables it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with azide-containing molecules, facilitating efficient conjugation. Its application is pivotal in the development of targeted cancer therapies, leveraging ADC technology for enhanced specificity in drug delivery.

Ald-Ph-amido-PEG3-C2-Pfp ester is a non-cleavable antibody-drug conjugate (ADC) linker that incorporates a polyethylene glycol (PEG) moiety. This linker enhances solubility and stability of the conjugate while providing effective attachment to the antibody. It is suitable for use in the development of ADCs, facilitating targeted delivery of therapeutic agents to specific cells and tissues in various cancer research applications.

Mc-Phe-Lys(Boc)-PAB is an antibody-drug conjugate (ADC) linker designed to facilitate the targeted delivery of therapeutic agents. It exhibits key biological activity by enhancing the stability and intracellular release of linked cytotoxic compounds. This reagent is primarily used in the development of ADCs for cancer treatment, allowing for improved efficacy and reduced off-target effects in research applications.

Fmoc-(D-Phe)-OSu is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). It facilitates the coupling between antibodies and cytotoxic drugs, ensuring the selective delivery of therapeutic agents to targeted cells. This compound is essential in the development of ADCs, enhancing their efficacy and stability in research applications related to cancer therapeutics and targeted treatment strategies.

DBCO-PEG4-Val-Ala-PAB is a cleavable ADC linker that effectively targets Cathepsin B for linker cleavage. The incorporation of Val-Ala linkers facilitates the controlled release of therapeutic agents, enhancing the efficacy of antibody-drug conjugates (ADCs). The DBCO moiety enables efficient Click Chemistry reactions, while the PEG spacer enhances the aqueous solubility of the compound, making it suitable for various biochemical applications.

Fmoc-Gly-Thr-OH is a synthetic linker commonly utilized in the development of antibody-drug conjugates (ADCs). This compound facilitates the conjugation of antibodies with cytotoxic drugs, enhancing targeted delivery to cancer cells. It plays a crucial role in pharmaceutical research focused on improving the efficacy and selectivity of therapeutic agents in cancer treatment.

N3-PEG5-aldehyde is a cleavable linker designed for use in antibody-drug conjugates (ADCs), featuring a five-unit polyethylene glycol (PEG) structure. This compound contains an azide functional group, enabling its application in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it is capable of participating in strain-promoted azide-alkyne cycloaddition (SPAAC) reactions with dibenzocyclooctyne (DBCO) or bicyclononyne (BCN) groups. N3-PEG5-aldehyde is valuable in the development of targeted therapeutics, enhancing drug delivery and efficacy.

Ald-Ph-amido-PEG3-C1-Boc is a polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) applications. This compound facilitates the conjugation of cytotoxic agents to antibodies, enhancing the selectivity and efficacy of targeted therapies. It operates by linking the drug payload to an antibody through a stable amide bond, which is critical for the development and optimization of ADCs in cancer research.

Mal-PEG4-bis-PEG3-DBCO is a cleavable linker designed for use in antibody-drug conjugates (ADCs), facilitating targeted delivery of therapeutics. This reagent features a DBCO group that enables strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules, allowing for efficient conjugation. Its PEGylated structure enhances solubility and provides stability in biological applications, making it suitable for ADC development and related research endeavors.

MC-Gly-Gly-Phe-Boc is a versatile ADC linker that facilitates the synthesis of antibody-drug conjugates, specifically with Trastuzumab. This compound plays a crucial role in cancer research by enabling targeted delivery of therapeutic agents, thereby enhancing the efficacy of cancer treatment. Its unique structure supports the development of advanced therapeutic strategies aimed at improving patient outcomes in oncology.

Me-Tet-PEG9-NHS is an antibody-drug conjugate (ADC) linker featuring a 9-unit polyethylene glycol (PEG) chain. This reagent enables a specific inverse electron demand Diels-Alder (iEDDA) reaction with trans-cyclooctene (TCO) functionalized compounds, facilitating targeted delivery of therapeutic agents. Its unique properties make it suitable for applications in the development of novel ADCs in cancer research and targeted therapies.

m-PEG5-MS is a PEG-based linker designed for antibody-drug conjugates (ADCs) and proteolysis-targeting chimeras (PROTACs). This cleavable linker facilitates the synthesis of PROTACs, enabling targeted degradation of specific proteins. Its key applications include drug development and cellular regulation studies, making it a versatile tool in therapeutic research and protein modulation.

Boc-Gly-Gly-Phe-Gly-OH TFA is a protease-cleavable linker designed for use in antibody-drug conjugates (ADCs). This self-assembling tetrapeptide features N- and C-terminal protection, facilitating targeted drug delivery. Its key biological activity includes enabling specific cleavage by proteases, thus enhancing the release of therapeutic agents in the desired cellular environment. This reagent is essential for researchers developing innovative ADC platforms in cancer therapy.

DBCO-PEG3 acetic-EVCit-PAB is a cleavable ADC linker that features a three-unit polyethylene glycol (PEG) chain. This compound facilitates the construction of antibody-drug conjugates (ADCs) by employing click chemistry through its dibenzocyclooctyne (DBCO) moiety, which engages in strain-promoted alkyne-azide cycloaddition (SPAAC) with azide-containing molecules. DBCO-PEG3 acetic-EVCit-PAB is integral in enhancing the specificity and efficacy of therapeutic agents in targeted cancer treatments, making it a valuable tool for bioconjugation research.

ALD-PEG4-OPFP is a cleavable polyethylene glycol (PEG) linker designed for antibody-drug conjugate (ADC) synthesis. This four-unit PEG linker facilitates the covalent attachment of cytotoxic drugs to antibodies, promoting targeted delivery and enhanced therapeutic efficacy. ALD-PEG4-OPFP is valuable for research applications focusing on ADC development, enabling the study of drug release and optimizing therapeutic strategies.

Amino-PEG11-OH is a non-cleavable linker composed of an 11-unit polyethylene glycol (PEG) moiety designed for use in antibody-drug conjugates (ADCs) and PROTAC (Proteolysis Targeting Chimera) synthesis. This PEG-based linker facilitates the conjugation of drugs to antibodies, enhancing therapeutic efficacy while maintaining stability. Additionally, it serves as an effective component in the development of PROTACs, enabling targeted protein degradation for advanced molecular research applications.

Boc-Phe-(Alloc)Lys-PAB-PNP is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This compound facilitates the selective release of cytotoxic agents upon internalization of the ADC, enhancing therapeutic efficacy while minimizing off-target effects. Its application is critical in the development of targeted cancer therapies, allowing for the precise delivery of drugs to tumor cells.

Boc-C2-Urea-bis(Boc)-C4-Urea-4-phenylacetic acid is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound facilitates the stable attachment of cytotoxic agents to antibodies, allowing for targeted therapy applications in cancer research. Its unique structure promotes selective release of the drug once internalized by target cells, enhancing therapeutic efficacy while minimizing off-target effects.

DBCO-PEG4-alkyne is a non-cleavable linker designed for antibody-drug conjugates (ADCs), featuring a 4-unit polyethylene glycol (PEG) chain. This compound serves as a versatile click chemistry reagent, incorporating an alkyne functional group that enables the efficient copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its application in ADC synthesis facilitates the stable conjugation of therapeutic agents, enhancing the efficacy and selectivity of targeted cancer treatments.

Azidoethyl-SS-propionic NHS ester is a cleavable linker specifically designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an azide functional group, enabling it to participate in click chemistry reactions, including copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with DBCO or BCN functionalities, making it a versatile tool for bioconjugation applications in chemical biology and targeted therapeutics.

Mal-PEG4-VC-PAB-DMEA is a cleavable linker featuring a Maleimide moiety utilized in the design of antibody-drug conjugates (ADCs). This compound facilitates the selective conjugation of cytotoxic agents to antibodies, enhancing targeted delivery to specific cancer cells. Its inherent stability and designed release mechanism make it a valuable tool for researchers developing ADCs in therapeutic and diagnostic applications.

Val-Cit-PABC-Ahx-May is a cleavable linker designed for use in antibody-drug conjugates (ADCs). It facilitates the selective release of therapeutics upon internalization by target cells, enhancing the efficacy of targeted cancer therapies. This linker is utilized in research applications focused on the development and optimization of ADCs for improved pharmacokinetics and therapeutic outcomes.

Propargyl-PEG1-SS-PEG1-propargyl is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This PEG-based reagent features an alkyne functionality, enabling its participation in copper-catalyzed azide-alkyne cycloaddition (CuAAC) reactions with azide-containing molecules. It is particularly useful for developing targeted therapeutics, facilitating the stable attachment of cytotoxic agents to antibodies while maintaining drug efficacy and specificity.

Biotin-sar-oh is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). It facilitates targeted delivery of cytotoxic agents by linking antibodies to drug molecules, enabling selective cancer cell targeting. This compound is essential for researchers focusing on ADC development and optimization, enhancing therapeutic efficacy while minimizing off-target effects.

Bis-PEG1-PFP ester is a non-cleavable linker designed for antibody-drug conjugate (ADC) synthesis, featuring a single unit of polyethylene glycol (PEG). This reagent facilitates the conjugation of antibodies with cytotoxic agents, maintaining stability during circulation. Its unique properties make it suitable for enhancing the therapeutic efficacy of ADCs while minimizing off-target effects, making it invaluable for cancer research and drug development.

(R)-8-Azido-2-(Fmoc-amino)octanoic acid is a non-cleavable linker for antibody-drug conjugates (ADCs), facilitating the synthesis of targeted therapeutics. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions with alkyne-containing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with entities that possess DBCO or BCN functionalities, making it a versatile tool in chemical biology and medicinal chemistry applications.

NO2-SPP-sulfo-Me is a cleavable linker designed for use in antibody-drug conjugates (ADCs). This reagent facilitates the attachment of cytotoxic agents to antibodies, enhancing targeted delivery to cancerous cells. Its unique structure allows for controlled release of the drug upon internalization, making it a valuable tool in cancer research and therapeutic development.

BCOT-PEF3-OPFP is a cleavable linker designed for the synthesis of antibody-drug conjugates (ADCs). This compound features an alkyne group that facilitates the copper-catalyzed azide-alkyne cycloaddition (CuAAc) reaction with azide-containing molecules. Its application in ADC development allows for enhanced targeting and controlled release of therapeutic agents, making it a valuable tool in cancer research and therapeutic applications.

MC-PEG2-NH2 is a cleavable linker designed for use in the synthesis of antibody-drug conjugates (ADCs). This reagent facilitates the conjugation of antibodies to cytotoxic drugs, enabling targeted delivery and enhancing therapeutic efficacy. Its unique structure provides stability in circulation while allowing for controlled release of the drug within the target cells, making it valuable for research in targeted cancer therapies and bioconjugate development.